铁调素

维基百科,自由的百科全书
跳到导航 跳到搜索
Hepcidin
PDB 1m4f EBI.jpg
Solution structure of hepcidin-25.[1]
鑑定
標誌Hepcidin
PfamPF06446
InterPro英语InterProIPR010500
 SCOP英语Structural Classification of Proteins1m4f / SUPFAM
 OPM英语Orientations of Proteins in Membranes database家族162
OPM英语Orientations of Proteins in Membranes database蛋白1m4e
hepcidin antimicrobial peptide
識別
符號 HAMP
Entrez 57817
HUGO 15598
OMIM 606464
RefSeq NM_021175
UniProt P81172
其他資料
基因座 19 q13.1


铁调素(英語:Hepcidin)是一种由肝脏产生的肽类激素,发现于2000年,是人类和其它哺乳动物铁离子代谢的主要调节者[2]。 铁调素可调节(抑制)铁通过肠粘膜的转运,从而防止铁吸收过多,维持体内正常铁含量。 铁调素还抑制肝细胞巨噬细胞(铁储存和运输的场所)的铁转运。 因此,在高铁调素水平(包括炎症状态)的状态下,由于铁被限制在巨噬细胞内,血清铁含量可能下降, 这可能会导致缺铁性贫血。 在人类中,HAMP是编码铁调素的基因。 也有研究发现,铁调素在鼠模型中具有抗炎性质,由于负反馈机制,炎症时铁调素水平可能会升高。[3]


结构[编辑]

功能[编辑]

历史[编辑]

临床意义[编辑]

参考文献[编辑]

  1. ^ PDB 1M4F; Hunter HN, Fulton DB, Ganz T, Vogel HJ. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J. Biol. Chem. October 2002, 277 (40): 37597–603. PMID 12138110. doi:10.1074/jbc.M205305200. 
  2. ^ Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. August 2003, 102 (3): 783–8. PMID 12663437. doi:10.1182/blood-2003-03-0672. 
  3. ^ De Domenico I, Zhang TY, Koening CL, Branch RW, London N, Lo E, Daynes RA, Kushner JP, Li D, Ward DM, Kaplan J. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J. Clin. Invest. July 2010, 120 (7): 2395–405. PMC 2898601. PMID 20530874. doi:10.1172/JCI42011. 
  4. ^ Rossi E. Hepcidin--the iron regulatory hormone. Clin Biochem Rev. August 2005, 26 (3): 47–9. PMC 1240030. PMID 16450011. 
  5. ^ Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. May 2009, 75 (9): 976–81. PMID 19212416. doi:10.1038/ki.2009.21. 
  6. ^ Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. September 2000, 480 (2–3): 147–50. PMID 11034317. doi:10.1016/S0014-5793(00)01920-7. 
  7. ^ Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. March 2001, 276 (11): 7806–10. PMID 11113131. doi:10.1074/jbc.M008922200. 
  8. ^ Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B, Iannelli A, Staccini-Myx A, Casanova D, Ben Amor I, Saint-Paul MC, Huet PM, Sadoul JL, Gugenheim J, Srai SK, Tran A, Le Marchand-Brustel Y. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology. September 2006, 131 (3): 788–96. PMID 16952548. doi:10.1053/j.gastro.2006.07.007. 
  9. ^ Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica. January 2008, 93 (1): 90–7. PMID 18166790. doi:10.3324/haematol.11705. 
  10. ^ Bregman DB, Morris D, Koch TA, He A, Goodnough LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am. J. Hematol. February 2013, 88 (2): 97–101. PMID 23335357. doi:10.1002/ajh.23354. 
  11. ^ Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, Muirhead K, Rao N, Roy CN, Andrews NC, Nemeth E, Follenzi A, An X, Mohandas N, Ginzburg Y, Rachmilewitz EA, Giardina PJ, Grady RW, Rivella S. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J. Clin. Invest. December 2010, 120 (12): 4466–77. PMC 2993583. PMID 21099112. doi:10.1172/JCI41717. 
  12. ^ Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin. Chem. December 2011, 57 (12): 1650–69. PMID 21989113. doi:10.1373/clinchem.2009.140053. 

延伸阅读[编辑]

外部链接[编辑]